Jing Hu, Ph.D, is currently a Scientist in Sangamo Therapeutics. She is working on bioanalytical assays to support preclinical and clinical studies. She graduated from University of Cincinnati with Ph.D degree in pharmacetical sciences in 2015, where she developed aptamer-mediated brain delivery system for therapeutic RNA/DNA to treat inflammation relevant CNS diseases, including parkinson's disease and stroke. After graduation, she got a contractor position in the department of Biochemical & Cellular Pharmacology in Genentech where she stayed for almost 1 year and mainly focused on the assay development and sample testing for PK and PD analysis of preclicial studies. Then Jing joined the antibody engineering group in Lakepharma in 2017. She was involved in therapeutic antibody generation using phase display. In 2018, she got the job in Bioanalytical group in Sangamo. She mainly worked on the bioanalytical strategies and assay development for gene therapy programs, which include biomarker assay (protein binding assay and enzymatic assay) and immunogenicity asssay.
Wednesday, October 28, 2020
11:30 AM – 12:00 PM ET